| PRKACB Protein | |
|---|---|
| Protein Name | Protein Kinase A Catalytic Subunit Beta |
| Gene | [PRKACB](/genes/prkacb) |
| UniProt ID | P22694 |
| PDB ID | 1J3H, 2Q23, 4DG5 |
| Molecular Weight | 40.6 kDa |
| Subcellular Localization | Cytoplasm, Nucleus |
| Protein Family | PKA family (cAMP-dependent protein kinase) |
| Enzyme Classification | EC 2.7.11.1 (Protein-Serine/Threonine Kinase) |
PRKACB (Protein Kinase A Catalytic Subunit Beta) is one of the catalytic subunits of the cAMP-dependent protein kinase (PKA), also known as protein kinase A (PKA). PKA is a serine/threonine-specific protein kinase that plays a central role in cellular signal transduction, mediating the effects of the second messenger cyclic adenosine monophosphate (cAMP). As one of the first protein kinases ever characterized[1], PKA has served as a paradigm for understanding kinase structure, regulation, and function. The enzyme is remarkably conserved across evolution, from yeast to mammals, reflecting its fundamental importance in cellular physiology[2].
PKA exists as a tetrameric holoenzyme composed of two regulatory subunits and two catalytic subunits. When intracellular cAMP levels rise in response to hormone binding to G-protein-coupled receptors (GPCRs), cAMP binds to the regulatory subunits, causing the release and activation of the catalytic subunits. PRKACB is one of four catalytic subunit isoforms (PRKACA, PRKACB, PRKACG, PRKACA2) expressed in mammalian tissues, with PRKACB showing particular enrichment in the brain[3]. Once active, PRKACB phosphorylates a vast array of substrate proteins, modulating their activity, localization, or interactions. This phosphorylation cascade regulates diverse cellular processes including metabolism, gene transcription, ion channel function, cell cycle progression, and—most relevant to neurodegeneration—synaptic plasticity, learning, and memory[4].
The cAMP/PKA signaling pathway is one of the most extensively studied cascades in the context of neurological function and dysfunction. Decades of research have established that PKA-mediated phosphorylation is essential for the formation and consolidation of memories[5], and alterations in this pathway have been strongly implicated in both Alzheimer's disease and Parkinson's disease[6]. Understanding the specific roles of the PRKACB isoform in neuronal function provides critical insight into therapeutic targeting strategies for these devastating disorders.
The human PRKACB gene is located on chromosome 1p31.1 and encodes a protein of 361 amino acids with a molecular weight of approximately 40.6 kDa. Like other PKA catalytic subunits, PRKACB exhibits the characteristic bilobal kinase fold consisting of a smaller N-terminal lobe (residues 1-120) rich in beta-strands and a larger C-terminal lobe (residues 150-300) that is primarily alpha-helical. The active site resides in the cleft between these two lobes, where ATP binding and catalysis occur. A flexible glycine-rich loop (residues 50-60) connects the N-terminal beta-strands and plays a critical role in positioning the phosphate donor ATP for catalysis.
The catalytic subunits share high sequence homology (>90% identical), with the major differences residing in the N-terminal variable regions that confer isoform-specific localization and regulation. PRKACB contains a unique N-terminal extension compared to PRKACA, which influences its targeting to specific cellular compartments and substrates.
The crystal structures of the PKA catalytic subunit were among the first protein kinase structures solved, providing foundational insights into kinase mechanism. The structure reveals a deep cleft where ATP binds, with the adenine ring fitting into a hydrophobic pocket and the phosphate groups positioned for phosphoryl transfer. The activation segment (residues 180-200) contains the activation loop whose phosphorylation is critical for full activity. In the active conformation, the activation loop is stabilized by interactions with the preceding helix, allowing substrate access to the active site.
Key structural features of PRKACB include:
PRKACB undergoes several important post-translational modifications that regulate its activity and stability:
PRKACB functions as the catalytic engine of the cAMP-dependent protein kinase cascade. The signaling pathway proceeds as follows:
This cascade provides remarkable signal amplification—a single activated receptor can generate hundreds of cAMP molecules, each capable of activating a PKA catalytic subunit that can phosphorylate numerous substrate molecules.
In neurons, PRKACB plays particularly important roles in synaptic plasticity, the cellular basis of learning and memory:
PRKACB phosphorylates numerous components of the synaptic vesicle cycle and neurotransmitter receptors:
PRKACB translocates to the nucleus where it phosphorylates key transcription factors:
PRKACB regulates neuronal excitability through phosphorylation of:
The canonical role of PKA in memory formation has been established through decades of research. Pharmacological inhibition of PKA in the amygdala blocks memory formation[7:1], while genetic manipulation of PKA subunits produces mice with profound memory deficits[8]. The pathway operates at multiple stages of memory processing:
Beyond neuronal function, PRKACB regulates fundamental cellular processes:
The cAMP/PKA signaling pathway is significantly dysregulated in Alzheimer's disease[6:1]. Multiple studies have documented:
In AD brains, CREB phosphorylation at the critical activating site Ser133 is reduced[9]. This deficit has several consequences:
PRKACB can phosphorylate tau protein at multiple sites relevant to AD pathology:
The balance between kinase (including PRKACB) and phosphatase activities determines tau phosphorylation state. In AD, this balance shifts toward hyperphosphorylation through both increased kinase activity and decreased phosphatase activity.
Synaptic PRKACB signaling is impaired in AD:
Restoring cAMP/PKA signaling is a therapeutic strategy under investigation:
In Parkinson's disease, PRKACB dysregulation contributes to dopaminergic neuron dysfunction:
Dopamine D1 receptor stimulation activates adenylate cyclase, increasing cAMP and activating PKA. In PD:
The cAMP/PKA pathway interacts with alpha-synuclein pathology in PD[11]:
PRKACB signaling has neuroprotective effects in dopaminergic neurons[12]:
PRKACB dysregulation has been implicated in several other conditions:
PRKACB interacts with numerous proteins forming a complex signaling network:
PDE inhibitors enhance cAMP signaling by preventing its degradation:
Walsh DA, et al. (1968). Cyclic AMP-dependent protein kinase. J Biol Chem 243:3763-3765[1:1]
Barad M, et al. (1998). Inhibition of PKA in the amygdala blocks memory formation. PNAS 95:15020-15025[7:2]
Abel T, et al. (1997). Genetic analysis of PKA function in memory. Curr Opin Neurobiol 7:835-840[4:1]
Huang FL, et al. (2004). Spatial learning and memory deficits in PKA mutant mice. Behav Neurosci 118:514-523[8:1]
Mondragon-Rodriguez S, et al. (2017). Phosphorylation of tau protein at Ser396. J Alzheimers Dis 58:361-375[10:1]
Wetzel S, et al. (2019). cAMP signaling in tauopathy. J Mol Neurosci 69:351-363[9:1]
Zhang G, et al. (2020). cAMP-PKA pathway alterations in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 100:109878[6:2]
Chen Y, et al. (2019). Dysregulation of cAMP/PKA signaling in dopaminergic neurons. J Parkinsons Dis 9:275-289[12:1]
Choi SH, et al. (2018). cAMP-PKA pathway in synucleinopathies. Neurobiol Dis 110:52-61[11:1]
Walsh DA, et al. Cyclic AMP-dependent protein kinase. Journal of Biological Chemistry. 1968. ↩︎ ↩︎
Sutherland EW, et al. Cyclic AMP and hormone action. Handbook of Experimental Pharmacology. 1983. ↩︎
Skålhegg BS, et al. Localization of the isoforms of the catalytic subunit of cAMP-dependent protein kinase. Journal of Biological Chemistry. 1992. ↩︎
Abel T, et al. Genetic analysis of PKA function in memory. Current Opinion in Neurobiology. 1997. ↩︎ ↩︎
Tully T, et al. Towards a molecular genetics of learning and memory. Cell. 1994. ↩︎
Zhang G, et al. cAMP-PKA pathway alterations in Alzheimer's disease. Progress in Neuropsychopharmacology and Biological Psychiatry. 2020. ↩︎ ↩︎ ↩︎
Barad M, et al. Inhibition of PKA in the amygdala blocks memory formation. Proceedings of the National Academy of Sciences. 1998. ↩︎ ↩︎ ↩︎
Huang FL, et al. Spatial learning and memory deficits in PKA mutant mice. Behavioral Neuroscience. 2004. ↩︎ ↩︎
Wetzel S, et al. cAMP signaling in tauopathy. Journal of Molecular Neuroscience. 2019. ↩︎ ↩︎
Mondragon-Rodriguez S, et al. Phosphorylation of tau protein at Ser396 regulates memory and synaptic plasticity. Journal of Alzheimer's Disease. 2017. ↩︎ ↩︎
Choi SH, et al. cAMP-PKA pathway in synucleinopathies. Neurobiology of Disease. 2018. ↩︎ ↩︎
Chen Y, et al. Dysregulation of cAMP/PKA signaling in dopaminergic neurons. Journal of Parkinson's Disease. 2019. ↩︎ ↩︎